Vera Therapeutics, Inc.
VERA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001831828
In the last 90 days, Vera Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 221 institutions reported holding it in 13F filings for Q2 2026, worth $3.34B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $2.17B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $1.33M in total
- 2
- 13F holdersQ2 2026, −8 vs. previous quarter
- 221
- 13F valueReported value at the end of Q2 2026
- $3.34B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$299.6M
- No comparable prior period
- Free cash flow, FY2025
- -$241.7M
- No comparable prior period
- Revenue, Q3 FY2026
- $10.3M
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 13.6M
- Shares sold short
- Change
- −3.65M
- −21.2% vs. previous
- Days to cover
- 7.17
- At average daily volume
Superinvestors holding VERA, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding VERA at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Vera Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 17, 2026 (view filing)4:28 PM ET | Sep 15 | 2 days | Fordyce MarshallPRESIDENT AND CEO | SSaleClass A Common Stock | −18.5K | $37.00 | −$684.5K | −7.3%235.2K after | 10b5-1 |
| Sep 4, 2026 (view filing)4:15 PM ET | Sep 2 | 2 days | Fordyce MarshallPRESIDENT AND CEO | SSaleClass A Common Stock | −18.5K | $35.12 | −$649.6K | −7.3%235.2K after | 10b5-1 |
| Aug 12, 2026 (view filing)6:42 PM ET | Jul 7 | 36 days | Fordyce MarshallPRESIDENT AND CEO | SSaleClass A Common Stock | −46.3K | $42.30 | −$1.96M | −16.4%235.2K after | Amended4 lots10b5-1 |
| Aug 12, 2026 (view filing)6:41 PM ET | Jun 23 | 50 days | Fordyce MarshallPRESIDENT AND CEO | SSaleClass A Common Stock | −18.5K | $37.93 | −$701.8K | −7.3%235.2K after | Amended2 lots10b5-1 |
| Aug 12, 2026 (view filing)6:39 PM ET | May 12 | 92 days | Fordyce MarshallPRESIDENT AND CEO | SSaleClass A Common Stock | −18.5K | $36.74 | −$679.7K | −7.3%235.2K after | Amended2 lots10b5-1 |
| Apr 15, 2026 (view filing) | Apr 14 | 1 day | Fordyce MarshallPRESIDENT AND CEO | SSaleClass A Common Stock | −23.0K | $44.05 | −$1.01M | −8.9%235.2K after | 3 lots10b5-1 |
| Feb 25, 2026 (view filing) | Feb 23 | 2 days | Skelton Laurence MatthewChief Commercial Officer | SSaleClass A Common Stock | −1.58K | $41.98 | −$66.4K | −2.4%64.2K after | |
| Feb 25, 2026 (view filing) | Feb 23 | 2 days | Brenner RobertChief Medical Officer | SSaleClass A Common Stock | −2.15K | $41.98 | −$90.3K | −4.1%50.9K after | |
| Feb 25, 2026 (view filing) | Feb 23 | 2 days | Grant SeanCHIEF FINANCIAL OFFICER | SSaleClass A Common Stock | −4.95K | $41.98 | −$207.8K | −4.2%114.2K after | |
| Feb 25, 2026 (view filing) | Feb 23 | 2 days | Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCR | SSaleClass A Common Stock | −3.12K | $41.98 | −$130.9K | −4.6%64.7K after |
Top 10 13F holders, Q2 2026
See all 221 holdersThe largest institutional positions in Vera Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 5,747,760 | $246.6M | 0.00% | +659,658+13.0% | Added |
| Avoro Capital Advisors LLC | 5,723,888 | $245.6M | 2.21% | −165,000−2.8% | Reduced |
| State Street Corp | 4,148,786 | $178.0M | 0.01% | +785,148+23.3% | Added |
| Price T Rowe Associates Inc | 4,012,936 | $172.2M | 0.02% | −561,094−12.3% | Reduced |
| Deep Track Capital, LP | 4,000,000 | $171.6M | 2.53% | −106,067−2.6% | Reduced |
| Deerfield Management Company, L.P. (Series C) | 3,916,400 | $168.1M | 1.75% | +194,300+5.2% | Added |
| Kynam Capital Management, LP | 2,890,059 | $124.0M | 6.85% | −508,165−15.0% | Reduced |
| Morgan Stanley | 2,799,459 | $120.1M | 0.01% | +2,430,699+659.2% | Added |
| Sofinnova Investments, Inc. | 2,793,987 | $119.9M | 6.40% | 00.0% | Unchanged |
| FMR LLC | 2,774,070 | $119.0M | 0.01% | +97,648+3.6% | Added |
Holders of 5% or more of VERA
See all 6 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Vera Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Avoro Capital Advisors LLC | 13G/A | 8.90%5.61M shares | – | Nov 14, 20242 filings | Feb 14, 2025 | SEC |
| BlackRock, Inc. | 13G/A | 7.40%5.34M shares | – | Jul 30, 20261 filing | Jul 30, 2026 | SEC |
| Price T Rowe Associates Inc | 13G/A | 6.40%4.57M shares | −1.30 ppfrom 7.70% | Nov 14, 20244 filings | May 15, 2026 | SEC |
| State Street Corp | 13G | 5.80%4.15M shares | New | Aug 7, 20261 filing | Aug 7, 2026 | SEC |
| Deep Track Capital, LP | 13G | 5.50%3.92M shares | New | Mar 11, 20261 filing | Mar 11, 2026 | SEC |